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Abstract
Despite progressive universal drug coverage and pharmaceutical policies found in other countries, Canada 
remains the only developed nation with a publicly funded healthcare system that does not include universal 
coverage for prescription drugs. In the absence of a national pharmacare plan, a province may choose to 
cover a specific sub-population for certain drugs. Although different provinces have individually attempted 
to extend coverage to certain subpopulations within their jurisdictions, out-of-pocket expenses on drugs 
and pharmaceutical products (OPEDP) accounts for a large proportion of out-of-pocket health expenses 
(OPHE) that are catastrophic in nature. Pharmaceutical drug coverage is a major source of public scrutiny 
among politicians and policy-makers in Canada. In this editorial, we focus on social inequalities in the burden 
of OPEDP in Canada. Prescription drugs are inconsistently covered under patchworks of public insurance 
coverage, and this inconsistency represents a major source of inequity of healthcare financing. Residents of 
certain provinces, rural households and Canadians from poorer households are more likely to be affected by 
this inequity and suffer disproportionately higher proportions of catastrophic out-of-pocket expenses on drugs 
and pharmaceutical products (COPEDP). Universal pharmacare would reduce COPEDP and promote a more 
equitable healthcare system in Canada. 
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Introduction
Equity has long been established as a vital component of 
any nation’s universal health system.1-6 Indeed, equity is 
recommended by the World Health Organization (WHO) 
as a motivating factor for a given nation’s universal health 
coverage that also lays the groundwork for any debates on 
public policy.2-5 The WHO3 states that equity manifests in 
healthcare primarily through fair health system financing 
and fair access to health services. More specifically, equitable 
healthcare financing includes the use of fair prepayment 
schemes and protection against catastrophic payments 
by individual citizens or households.3,7 Both equitable 
healthcare financing and utilization are respectively guided 
by the universal principles that healthcare should be financed 
according to ability-to-pay (ATP) and distributed according 
to need.8 Thus, equity and fairness in healthcare has been 
traditionally viewed, studied, and debated from the two 
perspectives: equity in healthcare financing and equity in 
healthcare utilization. 
Pharmaceutical or prescription drugs are an essential 
component of modern medicine. The WHO has stated 
that every nation should have universal access to essential 
drugs and medicines.4 Additional WHO reports3,5,6 outline 
the importance of having equitable pharmaceutical policies 
within a more extensive universal health system. Many 
nations with universal healthcare systems, including virtually 
every developed country, have enacted universal coverage for 
medically necessary prescription drugs and medicines. Despite 
progressive universal drug coverage and pharmaceutical 
policies found in other countries, Canada remains the only 
developed nation with universal health coverage that does not 
include universal coverage for prescription drugs. 
Canada’s healthcare system – affectionately known as 
“Medicare” – is a universal public health insurance system that 
covers residents for medically necessary hospital and physician 
services. Coordinated between the federal and provincial 
governments through the Canada Health Act, residents 
receive first-dollar coverage for necessary hospitalizations, 
physician appointments, and diagnostic exams regardless of 
which province they reside in, how old they are, or how much 
money they have.9 Notwithstanding the deep level of coverage 
for the health services currently covered, universal coverage 
of drugs has never been implemented in Canada. Provincial 
governments have individually implemented a variety of 
public drug coverage programs that alleviate some of the 
burden on some particular classes of residents, including 
low-income households, seniors, and those households using 
social assistance.2,10,11 Significant interprovincial variation 
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in drug coverage has led to notable variation in the burden 
of out-of-pocket expenses on drugs and pharmaceutical 
products (OPEDP).11
Since Medicare was first introduced in Canada by 
Saskatchewan Premier Tommy Douglas and his social 
democratic government in 1947,12 there has been no shortage 
of calls to include universal prescription drug coverage for 
all Canadian residents. Royal Commissions, such as the 
Hall Commission (1964)13 and the Romanow Commission 
(2002),14 as well as numerous recent provincial and federal 
government reports2,10,12,15 have recommended the adoption 
of universal pharmaceutical drug coverage in some form. 
Several empirical studies have demonstrated the financial 
hardships suffered by Canadians because of the uninsured 
costs of pharmaceutical drugs.11,16,17 Even with brief periods 
of public attention in the past, the topic of pharmacare has 
remained relatively untouched by Canadian policy-makers 
because of a lack of electoral incentives and general concern 
over costs to be incurred by government18,19 – despite robust 
cost proposals by Morgan and colleagues,20,21 and Wolfson 
and Morgan.22 Recently, however, pharmacare has become 
a central topic of public discussion and political discourse, 
which is demonstrated by its inclusion in the platforms of 
major political parties for the recent federal election and the 
establishment of the federal government’s Advisory Council 
on the Implementation of National Pharmacare.10
As Canada looks to implement universal pharmacare 
over the coming years, it is important for policy-makers 
to recognize the critical role of equity in the financing and 
delivery of these new public services. Indeed, the WHO5 
explains that upon implementing any universal health 
coverage, nations need to consider the fair distribution of 
health services, cost-effectiveness, and fair contribution to 
the health system. In other words, the services should be 
distributed based on need and financed based on ATP, while 
being as cost-effective as possible, to achieve the maximum 
benefit to the target population.5 In this editorial, we briefly 
highlight equity concerns associated with the current 
pharmacare in Canada. We focus on social inequalities in the 
financing of drugs and pharmaceutical products in Canada. 
We provide supporting statistics using pooled data from six 
nationally representative Survey of Household Spending 
(SHS) conducted by Statistics Canada between 2010 and 2015 
(n = 33 367 households) to empirically demonstrate the equity 
concerns of the current financing of drugs and pharmaceutical 
products in Canada. Specifically, we assess provincial, rural-
urban, and socioeconomic inequalities in the financing of 
OPEDP in Canada.
Provincial Variations in OPEDP
Figure 1 shows the mean annual equivalized OPEDP for 
the households of each province over the period between 
2010 and 2015[1]. There exist cross-provincial differences 
in pharmaceutical coverage, which are demonstrated in the 
varying levels of mean equivalized OPEDP and proportions of 
OPEDP to equivalized total household out-of-pocket health 
expenses (OPHE). As illustrated in the figure, Newfoundland 
and Labrador had the lowest mean OPEDP in the country, 
whereas British Columbia had the highest. The proportion of 
mean equivalized OPEDP to OPHE ranges from 46% (British 
Columbia) to 57% (New Brunswick and Manitoba).
There are also variations in the number of households 
facing catastrophic out-of-pocket expenses on drugs and 
pharmaceutical products (COPEDP) across Canadian 
provinces (see Figure 2). The percentage of households in a 
province facing COPEDP of 3% and 6% of total household 
consumption[2] range from 14% to 22% and 5% to 10%, 
respectively. The considerable range in households facing 
COPEDP between provinces over the study period is a result 
of differences in provincial public health insurance schemes. 
The absence of universal pharmacare produces variation in 
drug payments made by the households of different provinces.
Rural-Urban Differences in OPEDP
Figure 3 demonstrates the share of drugs and pharmaceutical 
expenses from total OPHE from 2010-2015 for Canada and 
urban and rural households [3]. Rural households had a higher 
proportion of OPEDP from total OPHE (56%) than urban 
households (48%). Additionally, the percentage of households 
facing COPEDP was higher in rural households than urban 
Figure 1. Mean Equivalized Annual OPEDP and Other OPHE Across Canadian Provinces: 2010-2015. 
Abbreviations: NL, Newfoundland and Labrador; PE, Prince Edward Island; NS, Nova Scotia; NB, New Brunswick; QC, Quebec; ON, Ontario; MB, Manitoba; SK, 
Saskatchewan; AB, Alberta; BC, British Columbia; OPHE, out-of-pocket health expenses; OPEDP, out-of-pocket expenses on drugs and pharmaceutical products. 
Source: Authors’ calculation.
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households for both the 3% (rural area: 24%; urban area:16%) 
and 6% (rural area: 10%; urban area: 5%) thresholds (see 
Figure 4). Overall, 18% of Canadian households face COPEDP 
totaling at least 3% of their total household consumptions. 
When this threshold is raised to 6%, 7% of Canadians still 
suffered COPEDP between 2010 and 2015.
Socioeconomic Differences in OPEDP
Figure 5 features the proportion of households with COPEDP 
broken down by five socioeconomic status (SES, as measured 
by equivalized household total consumption) quintiles. Figure 
5A uses the catastrophic expense threshold of 3% of total 
household consumption, and Figure 5B uses the threshold of 
6%. Regardless of the threshold, both figures highlight two 
clear patterns. First, the households with the lowest SES had 
the highest proportion of COPEDP with progressively lower 
proportions as the SES quintiles increase. In other words, as 
household SES increases the proportions of households with 
COPEDP decrease. The second pattern observed in both 
figures is the variation of proportions of COPEDP across five 
SES quintiles. For the lowest SES quintile households, there is 
substantial variation in the proportion of households facing 
catastrophic drug expenses across the provinces, whereas the 
lowest amount of variation is seen in the highest SES quintile. 
In other words, low SES households suffer from substantial 
variation in COPEDP across provinces that does not exist for 
high SES households.
Concluding Remarks
Equity stands as a long-standing goal of Canada’s healthcare 
system and is at the heart of progressive pharmaceutical drug 
policy found across the Canadian provinces.9,20 This editorial 
sought to highlight the equity concerns of the current 
pharmacare in Canada. Politicians in provincial legislatures 
across Canada have passed a variety of pharmaceutical 
drug insurance policies with good intentions, but they have 
achieved mixed results. Especially in the absence of universal 
pharmacare, inequality in financial contributions for drugs 
and pharmaceutical products and levels of COPEDP can 
be found across the provinces. Moreover, these provincial 
inequalities are compounded across rural and urban areas as 
well as different levels of SES; lower levels of SES households 
Figure 2. Proportion of Households With COPEDP Across Canadian Provinces Between 2010 and 2015: 3% and 6% of Total Household Consumption. 
Abbreviations: NL, Newfoundland and Labrador; PE, Prince Edward Island; NS, Nova Scotia; NB, New Brunswick; QC, Quebec; ON, Ontario; MB, Manitoba; SK, 
Saskatchewan; AB, Alberta; BC, British Columbia; COPEDP, catastrophic out-of-pocket expenses on drugs and pharmaceutical products; OPEDP, out-of-pocket 
expenses on drugs and pharmaceutical products. Source: Authors’ calculation.
Figure 3. Share of OPDE From Total OPHE in Urban and Rural Areas in 
Canada: 2010-2015. 
Abbreviations: OPDE, out-of-pocket expenses on drugs and pharmaceutical 
products; OPHE, out-of-pocket health expenses. Source: Authors’ calculation.
Figure 4. Proportion of Households With COPEDP by Urban and Rural Areas in 
Canada Between 2010 and 2015: 3% and 6% of Total Household Consumption. 
Abbreviations: COPEDP, catastrophic out-of-pocket expenses on drugs and 
pharmaceutical products; OPEDP, out-of-pocket expenses on drugs and 
pharmaceutical products. Source: Authors’ calculation.
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were found to have higher proportions of COPEDP. 
The considerable differences in provincial policies in 
Canada have led to people in different provinces receiving 
different levels of pharmaceutical drug coverage. These 
variations, in turn, result in substantial inequalities in OPEDP 
and COPEDP across provinces. Both rural residents and low-
SES residents are especially vulnerable to COPEDP. These 
social inequalities are compounded by other “invisible costs” 
to society, such as cost-related nonadherence to prescriptions 
medications.23,24 Universal pharmaceutical drug coverage in 
Canada would reduce system-level inequality and effectively 
reduce social inequalities in COPEDP. 
It is important to note that all types of OPHE are inequitable 
by their nature.17,25 Thus, OPHE other than drugs and 
pharmaceutical products costs contribute to overall health 
system inequity should be given their due consideration. As 
OPEDP constitute a large portion of total OPHE in Canada, 
the implementation of universal pharmacare would be a large 
step towards reducing OPHE and promoting a more equitable 
healthcare system in Canada.
Acknowledgements
We accessed the SHS at the Statistics Canada’s Atlantic 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
0%
5%
10%
15%
20%
25%
30%
35%
40%
45%
1 (Poorest) 2 3 4 5 (Richest)
A) OPEDP reaching 3% treshold 
0%
5%
10%
15%
20%
25%
1 (Poorest) 2 3 4 5 (Richest)
B) OPEDP reaching 6% treshold 
NL PE NS NB
QC ON MB SK
AB BC Canada
Figure 5. Proportion of Households With COPEDP in 5 SES Quintiles Across 
Canadian Provinces Between 2010 and 2015: 3% and 6% of Total Household 
Consumption. Abbreviations: NL, Newfoundland and Labrador; PE, Prince 
Edward Island; NS, Nova Scotia; NB, New Brunswick; QC, Quebec; ON, 
Ontario; MB, Manitoba; SK, Saskatchewan; AB, Alberta; BC, British Columbia; 
COPEDP, catastrophic out-of-pocket expenses on drugs and pharmaceutical 
products; SES, socioeconomic status; OPEDP, out-of-pocket expenses on 
drugs and pharmaceutical products. Note: Proportions of households with 
COPEDP in five SES quintiles were not reported for PE in panel B of the figure 
as per the data disclosure policy of Statistics Canada’s Research Data Centres 
for small cell sizes (fewer than 5 unweighted households with the COPEDP in 
one of the SES quartiles). 
Source: Authors’ calculation. 
Research Data Centre (ARDC) at Dalhousie University, 
Halifax, NS, Canada which is part of the Canadian Research 
Data Centre Network (CRDCN), Hamilton, ON, Canada. We 
would like to thank the CRDCN for facilitating the access 
to the SHS and the ARDC analyst Heather Hobson for her 
support and assistance.
Ethical issues
We accessed the SHS through Statistics Canada’s Research Data Centre 
(RDC). Data accessed through the RDC, which follows strict disclosure 
protocols according to the Statistics Canada Acts, is exempt from the research 
ethics review board. 
Competing interests
Authors declare that they have no competing interests. 
Authors’ contributions
Both authors contributed to the conception and design of the study. MH 
performed the analysis and SE helped with the analysis. Both authors 
contributed to drafting and revising of the editorial.
Authors’ affiliations
1School of Health Administration, Dalhousie University, Halifax, NS, Canada. 
2Schulich School of Law, Dalhousie University, Halifax, NS, Canada.
Endnotes
[1] As per the Organization for Economic Co-operation and Development 
(OECD) publications,26,27 households’ OPEDP and OPHE were equivalized by 
dividing them by the square root of household size when we calculated the 
mean household OPEDP and OPHE. 
[2] Catastrophic payments for healthcare are defined as exceeding a certain 
fraction of household ATP (eg, income or consumptions) in a given period, 
generally one year. This method aims to demonstrate the disruptive impact of 
health expenses on households’ living standards because of large healthcare 
expenditures.28 Although budget share (share of healthcare payments from 
total income/consumption) is used extensively in the current studies, there 
is no consensus on the threshold of catastrophic payments in the literature. 
The current studies11,16,17,25,29-32 have used the threshold between 3% of budget 
share to 40% of the capacity to pay (ie, income/consumption minus subsistence 
expenditure requirements). Similar to the threshold ranges used in the Statistics 
Canada’s report,33 we used 3 and 6% of household consumption as the cut-off.
[3] As per the definition of Statistics Canada,34 urban residential regions were 
defined as population centres with at least 30 000 people.
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